Selected research
Industry Research
Passive Immunizing Drugs Industry Research Report 2026
Market perspective
The global Passive Immunizing Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Passive Immunizing Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Passive Immunizing Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Passive Immunizing Drugs include Xingmeng Biopharmaceuticals (Suzhou), Wuhan Institute of Biological Products, Sichuan Yuanda Shuyang Pharmaceutical, Shanxi Kangbao Biological Product, Sharon Bio-Medicine, Hualan Biological Engineering, North China Pharmaceutical, Sinopharm Group and Zydus Lifesciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Passive Immunizing Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Passive Immunizing Drugs Market by Company
Xingmeng Biopharmaceuticals (Suzhou)
Wuhan Institute of Biological Products
Sichuan Yuanda Shuyang Pharmaceutical
Shanxi Kangbao Biological Product
Sharon Bio-Medicine
Hualan Biological Engineering
North China Pharmaceutical
Sinopharm Group
Zydus Lifesciences
Serum Institute of India
Sanofi Pasteur
Kedrion Biopharma
Kamada
Haffkine Bio-Pharmaceutical
Grifols
Bharat Biotech
Passive Immunizing Drugs Segment by Type
Rabies Immunoglobulin
Rabies Virus Monoclonal Antibody
Anti-rabies Serum
Passive Immunizing Drugs Segment by Application
Category II Exposure
Category III Exposure
Passive Immunizing Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Passive Immunizing Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Passive Immunizing Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Passive Immunizing Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Passive Immunizing Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Passive Immunizing Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Passive Immunizing Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rabies Immunoglobulin
- Rabies Virus Monoclonal Antibody
- Anti-rabies Serum
Applications
- Category II Exposure
- Category III Exposure
Companies covered
- Xingmeng Biopharmaceuticals (Suzhou)
- Wuhan Institute of Biological Products
- Sichuan Yuanda Shuyang Pharmaceutical
- Shanxi Kangbao Biological Product
- Sharon Bio-Medicine
- Hualan Biological Engineering
- North China Pharmaceutical
- Sinopharm Group
- Zydus Lifesciences
- Serum Institute of India
- Sanofi Pasteur
- Kedrion Biopharma
- Kamada
- Haffkine Bio-Pharmaceutical
- Grifols
- Bharat Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Passive Immunizing Drugs Market Size (2021-2032)
- 2.2.2 Global Passive Immunizing Drugs Sales (2021-2032)
- 2.2.3 Global Passive Immunizing Drugs Market Average Price (2021-2032)
- 2.3 Passive Immunizing Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rabies Immunoglobulin
- 2.3.3 Rabies Virus Monoclonal Antibody
- 2.3.4 Anti-rabies Serum
- 2.4 Passive Immunizing Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Category II Exposure
- 2.4.3 Category III Exposure
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Passive Immunizing Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Passive Immunizing Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Passive Immunizing Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Passive Immunizing Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Passive Immunizing Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Passive Immunizing Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Passive Immunizing Drugs, Product Type & Application
- 3.8 Global Manufacturers of Passive Immunizing Drugs, Established Date
- 3.9 Global Passive Immunizing Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Xingmeng Biopharmaceuticals (Suzhou)
- 4.1.1 Xingmeng Biopharmaceuticals (Suzhou) Company Information
- 4.1.2 Xingmeng Biopharmaceuticals (Suzhou) Business Overview
- 4.1.3 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Product Portfolio
- 4.1.5 Xingmeng Biopharmaceuticals (Suzhou) Recent Developments
- 4.2 Wuhan Institute of Biological Products
- 4.2.1 Wuhan Institute of Biological Products Company Information
- 4.2.2 Wuhan Institute of Biological Products Business Overview
- 4.2.3 Wuhan Institute of Biological Products Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Wuhan Institute of Biological Products Passive Immunizing Drugs Product Portfolio
- 4.2.5 Wuhan Institute of Biological Products Recent Developments
- 4.3 Sichuan Yuanda Shuyang Pharmaceutical
- 4.3.1 Sichuan Yuanda Shuyang Pharmaceutical Company Information
- 4.3.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview
- 4.3.3 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Product Portfolio
- 4.3.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments
- 4.4 Shanxi Kangbao Biological Product
- 4.4.1 Shanxi Kangbao Biological Product Company Information
- 4.4.2 Shanxi Kangbao Biological Product Business Overview
- 4.4.3 Shanxi Kangbao Biological Product Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shanxi Kangbao Biological Product Passive Immunizing Drugs Product Portfolio
- 4.4.5 Shanxi Kangbao Biological Product Recent Developments
- 4.5 Sharon Bio-Medicine
- 4.5.1 Sharon Bio-Medicine Company Information
- 4.5.2 Sharon Bio-Medicine Business Overview
- 4.5.3 Sharon Bio-Medicine Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sharon Bio-Medicine Passive Immunizing Drugs Product Portfolio
- 4.5.5 Sharon Bio-Medicine Recent Developments
- 4.6 Hualan Biological Engineering
- 4.6.1 Hualan Biological Engineering Company Information
- 4.6.2 Hualan Biological Engineering Business Overview
- 4.6.3 Hualan Biological Engineering Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hualan Biological Engineering Passive Immunizing Drugs Product Portfolio
- 4.6.5 Hualan Biological Engineering Recent Developments
- 4.7 North China Pharmaceutical
- 4.7.1 North China Pharmaceutical Company Information
- 4.7.2 North China Pharmaceutical Business Overview
- 4.7.3 North China Pharmaceutical Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 North China Pharmaceutical Passive Immunizing Drugs Product Portfolio
- 4.7.5 North China Pharmaceutical Recent Developments
- 4.8 Sinopharm Group
- 4.8.1 Sinopharm Group Company Information
- 4.8.2 Sinopharm Group Business Overview
- 4.8.3 Sinopharm Group Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sinopharm Group Passive Immunizing Drugs Product Portfolio
- 4.8.5 Sinopharm Group Recent Developments
- 4.9 Zydus Lifesciences
- 4.9.1 Zydus Lifesciences Company Information
- 4.9.2 Zydus Lifesciences Business Overview
- 4.9.3 Zydus Lifesciences Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Zydus Lifesciences Passive Immunizing Drugs Product Portfolio
- 4.9.5 Zydus Lifesciences Recent Developments
- 4.10 Serum Institute of India
- 4.10.1 Serum Institute of India Company Information
- 4.10.2 Serum Institute of India Business Overview
- 4.10.3 Serum Institute of India Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Serum Institute of India Passive Immunizing Drugs Product Portfolio
- 4.10.5 Serum Institute of India Recent Developments
- 4.11 Sanofi Pasteur
- 4.11.1 Sanofi Pasteur Company Information
- 4.11.2 Sanofi Pasteur Business Overview
- 4.11.3 Sanofi Pasteur Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sanofi Pasteur Passive Immunizing Drugs Product Portfolio
- 4.11.5 Sanofi Pasteur Recent Developments
- 4.12 Kedrion Biopharma
- 4.12.1 Kedrion Biopharma Company Information
- 4.12.2 Kedrion Biopharma Business Overview
- 4.12.3 Kedrion Biopharma Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Kedrion Biopharma Passive Immunizing Drugs Product Portfolio
- 4.12.5 Kedrion Biopharma Recent Developments
- 4.13 Kamada
- 4.13.1 Kamada Company Information
- 4.13.2 Kamada Business Overview
- 4.13.3 Kamada Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Kamada Passive Immunizing Drugs Product Portfolio
- 4.13.5 Kamada Recent Developments
- 4.14 Haffkine Bio-Pharmaceutical
- 4.14.1 Haffkine Bio-Pharmaceutical Company Information
- 4.14.2 Haffkine Bio-Pharmaceutical Business Overview
- 4.14.3 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Product Portfolio
- 4.14.5 Haffkine Bio-Pharmaceutical Recent Developments
- 4.15 Grifols
- 4.15.1 Grifols Company Information
- 4.15.2 Grifols Business Overview
- 4.15.3 Grifols Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Grifols Passive Immunizing Drugs Product Portfolio
- 4.15.5 Grifols Recent Developments
- 4.16 Bharat Biotech
- 4.16.1 Bharat Biotech Company Information
- 4.16.2 Bharat Biotech Business Overview
- 4.16.3 Bharat Biotech Passive Immunizing Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Bharat Biotech Passive Immunizing Drugs Product Portfolio
- 4.16.5 Bharat Biotech Recent Developments
5 Global Passive Immunizing Drugs Market Scenario by Region
- 5.1 Global Passive Immunizing Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Passive Immunizing Drugs Sales by Region: 2021-2032
- 5.2.1 Global Passive Immunizing Drugs Sales by Region: 2021-2026
- 5.2.2 Global Passive Immunizing Drugs Sales by Region: 2027-2032
- 5.3 Global Passive Immunizing Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Passive Immunizing Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Passive Immunizing Drugs Revenue by Region: 2027-2032
- 5.4 North America Passive Immunizing Drugs Market Facts & Figures by Country
- 5.4.1 North America Passive Immunizing Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Passive Immunizing Drugs Sales by Country (2021-2032)
- 5.4.3 North America Passive Immunizing Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Passive Immunizing Drugs Market Facts & Figures by Country
- 5.5.1 Europe Passive Immunizing Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Passive Immunizing Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Passive Immunizing Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Passive Immunizing Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Passive Immunizing Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Passive Immunizing Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Passive Immunizing Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Passive Immunizing Drugs Market Facts & Figures by Country
- 5.7.1 South America Passive Immunizing Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Passive Immunizing Drugs Sales by Country (2021-2032)
- 5.7.3 South America Passive Immunizing Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Passive Immunizing Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Passive Immunizing Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Passive Immunizing Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Passive Immunizing Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Passive Immunizing Drugs Sales by Type (2021-2032)
- 6.1.1 Global Passive Immunizing Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Passive Immunizing Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Passive Immunizing Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Passive Immunizing Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Passive Immunizing Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Passive Immunizing Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Passive Immunizing Drugs Sales by Application (2021-2032)
- 7.1.1 Global Passive Immunizing Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Passive Immunizing Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Passive Immunizing Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Passive Immunizing Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Passive Immunizing Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Passive Immunizing Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Passive Immunizing Drugs Value Chain Analysis
- 8.1.1 Passive Immunizing Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Passive Immunizing Drugs Production Mode & Process
- 8.2 Passive Immunizing Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Passive Immunizing Drugs Distributors
- 8.2.3 Passive Immunizing Drugs Customers
9 Global Passive Immunizing Drugs Analyzing Market Dynamics
- 9.1 Passive Immunizing Drugs Industry Trends
- 9.2 Passive Immunizing Drugs Industry Drivers
- 9.3 Passive Immunizing Drugs Industry Opportunities and Challenges
- 9.4 Passive Immunizing Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst